StockData
Ocular Therapeutix, Inc logo

Ocular Therapeutix, Inc (OCUL) company profile

OCULNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 9, 2026Score 3/3032% above fair value
$6.01−0.20 (-3.22%)

Close on Nov 16, 2026Market cap $1.32BP/E –Yield –

About Ocular Therapeutix

Pharmaceutical Preparations, SIC 2834

Ocular Therapeutix, Inc. is a biopharmaceutical company focused on the development and commercialization of therapies for eye diseases and conditions using its proprietary bioresorbable hydrogel-based formulation technology, ELUTYX. Its primary commercial product is DEXTENZA, which is indicated for the treatment of ocular inflammation and pain following ophthalmic surgery and ocular itching associated with allergic conjunctivitis. In addition, the company develops investigational therapies including AXPAXLI, a product candidate in clinical evaluation for wet age-related macular degeneration and non-proliferative diabetic retinopathy, as well as OTX-TIC for open-angle glaucoma and ocular hypertension.

The company conducts its operations and research activities in the United States and maintains corporate collaborations, including a licensing agreement with AffaMed Therapeutics Limited covering territories in mainland China, Taiwan, Hong Kong, Macau, South Korea, and Southeast Asian nations. Ocular Therapeutix operates separate single-site manufacturing facilities for commercial inventory and clinical product candidates, and its principal executive offices are located in Bedford, Massachusetts.

Summary of the business section of Ocular Therapeutix's latest annual report, written by StockData.

Company profile

Company

Legal name
Ocular Therapeutix, Inc
Headquarters
Bedford, MA
Address
14 Crosby Drive, 3rd Floor 01730
Phone
(781) 357-4000
Website
ocutx.com
Employees
325, Dec 31, 2025
Industry
Pharmaceutical Preparations
Incorporated in
Delaware
Fiscal year ends
December 31
Auditor
PricewaterhouseCoopers LLP, Boston, Massachusetts

Stock & identifiers

Ticker
OCUL
Exchange
Nasdaq
IPO date
Jul 25, 2014
Shares outstanding
220M, Jul 31, 2026
Public float
$1.60B, Jun 30, 2025
Filer category
Large accelerated filer
SEC CIK
1393434
CUSIP
67576A100
ISIN
US67576A1007
FIGI
BBG001J1BZV0
Share class FIGI
BBG001V0FT93
LEI
529900ABAWFXOHSIHG03
EIN
00-0000000

Executives and directors

Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years

NamePositionShares owned
Pravin DugelSee Remarks, Director3,270,332
Namrata SarojChief Business Officer220,522
Todd AndermanChief Legal Officer140,484
Peter KaiserChief Development Officer254,388
Jeffrey S. HeierChief Scientific Officer307,457
Donald NotmanChief Operating Officer366,529
Sanjay NayakChief Strategy Officer326,898
Jason Shand RobinsChief Financial Officer68,097
Nadia WaheedChief Medical Officer300,079
David Wayne RobinsonGlobal CCO136,000
Steve Lawrence MeyersChief Commercial Officer217,628
Riad SherifDirector28,000
Adrienne L. GravesDirector64,000
Seung Suh HongDirector60,933
Leslie J. WilliamsDirector65,433
Charles M. WardenDirector100,464
Richard L. Lindstrom MdDirector304,492
Merilee RainesDirector60,933

CEO pay and shareholder return

Pay versus performance table from the proxy statement

Fiscal yearCEO total payCEO pay actually paidOther executives (avg)Value of $100 investedPeer group
FY2025$35.95M$57.53M$3.52M$59$120
FY2024
Dugel
$18.57M$9.65M$6.61M$41$91
FY2024
Mattessich
$8.78M$5.83M$6.61M$41$91
FY2023$3.28M$1.03M$1.41M$22$92
FY2022$4.10M-$2.09M$1.51M$14$89
FY2021$7.10M-$4.22M$3.61M$34$99

“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.

Executive compensation, fiscal 2025

Summary compensation table from the latest proxy statement

ExecutiveSalaryBonusStock awardsOption awardsOtherTotalvs. prior year
Pravin U. Dugel, M.D.
Executive Chair, President and Chief Executive Officer
$819.20K$890.88K$18.61M$15.57M$61.88K$35.95M+94%
Donald Notman
Chief Operating Officer and Chief Financial Officer
$560.18K$406.13K$855.60K$1.85M$2.88K$3.67M+77%
Nadia Waheed, M.D.
Chief Medical Officer
$536.67K$398.75K$1.09M$2.35M$378$4.38M–
Sanjay Nayak, M.B.B.S., Ph.D.
Chief Strategy Officer
$510.00K$332.78K$825.84K$1.79M$2.88K$3.46M–
Steve Meyers
Chief Commercial Officer
$510.00K$295.80K$550.56K$1.19M$2.88K$2.55M–

Stock and option awards are grant-date fair values, not realized pay. “Other” includes pension value changes and all other compensation. Source proxy statement.

IPO

From the final prospectus (Form 424B4) and the first day of trading

Offering

Type
Initial public offering
Final prospectus filed
Jul 25, 2014
Securities offered
5,000,000
Exchange
Nasdaq
First trading day
Jul 25, 2014
First-day close
$13.15
Lock-up ends (est.)
Jan 21, 2015

Lock-up end is estimated as 180 days after the first trading day; the prospectus sets the actual terms.

Employees

Headcount reported in annual reports

“As of December 31, 2025, we had 325 full-time employees.”

Corporate history

Events identified from SEC filings

DateEventDetails
Jul 25, 2014IPOInitial public offering priced (424B4 prospectus)
Jul 21, 2014ListingRegistration of securities on an exchange (Form 8-A)
Jul 2, 2009Name changeName changed from I-THERAPEUTIX INC to Ocular Therapeutix, Inc

See a number that looks wrong?